King, H.A.D., et al. Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. J Virol, 2026 Jul 27, e0038926. PMID: 42505121

This paper presents a comprehensive evaluation of the next-generation liposomal saponin-based adjuvant, ALFQ, in a primate model of HIV-1 vaccination, highlighting its capacity to elicit rapid, broad, and durable humoral and cellular immune responses. Unlike traditional adjuvants such as alum, ALFQ incorporates QS-21, a saponin known to enhance cross-presentation and induce robust CD8+ T cell responses. This feature was unexpectedly pronounced in this study. The unique aspect of this research lies in demonstrating potent CD8+ T cell responses alongside high-titer antibodies within a protein-based vaccine context. 

A central challenge in HIV vaccine development is generating durable, broad, and potent immune responses; therefore, this study emphasizes the potential of ALFQ to enhance vaccine efficacy by stimulating multiple facets of the immune response. Although the vaccine failed to confer protection against heterologous SHIV challenge, the findings underscore ALFQ’s potential for significantly amplifying immune responses against difficult pathogens, making this work a critical step forward in understanding how saponin-based adjuvants can be optimized for broad immunogenicity, with implications extending beyond HIV to other infectious diseases.

Click here to access the full scientific paper.